This is the first study to utilize clinical PET/CT data from GC patients and in vivo PET/CT detection in mice to analyze the correlation between NAT10 expression and glucose metabolism, providing an excellent biomarker and molecular target for the diagnosis and treatment of clinical GC patients. Here, NAT10 is linked to gastric cancer.